Author: Anirban Nandi
Abstract: Tuberculosis (TB) in children remains a significant public health issue, especially in regions with high TB prevalence. Effective treatment options for paediatric patients are crucial to ensure rapid recovery, reduce disease transmission, and prevent drug resistance. This paper explores the efficacy and safety of immediate-release anti-tubercular formulations specifically designed for paediatric use. Immediate-release formulations allow the active drug ingredients to be released quickly in the body, leading to a faster therapeutic response. However, concerns exist regarding their safety and effectiveness in children, who have different pharmacological needs than adults. The study reviews current research and clinical data to evaluate the impact of these medications on treatment outcomes, side effects, and overall safety in children with TB. We aim to determine whether immediate-release formulations effectively achieve the desired therapeutic levels without causing harmful side effects. The findings highlight the potential of immediate-release anti-tubercular medications to improve treatment adherence and clinical outcomes in young patients. However, close monitoring and further research are recommended to ensure these formulations meet paediatric safety standards. This paper contributes to the development of optimal TB treatment protocols for children, aiming for faster recovery and better quality of life for paediatric TB patients.
Keywords: Paediatric Tuberculosis, Immediate-Release Formulations, Anti-Tubercular Drugs, Paediatric Pharmacology, Tuberculosis Treatment, Drug Safety in Children, Clinical Efficacy
Page No-